What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?
Earlier Wednesday we could detect a distinct disturbance in the biotech force as some careful students of clinicaltrials.gov picked up on some major — and recently filed — changes in the timelines listed for a readout on Gilead’s $GILD closely-watched NASH drug selonsertib.
STELLAR 4, their Phase III study for compensated cirrhosis due to NASH, and STELLAR 3, on advanced NASH and bridging F3 fibrosis, had been given near-term planned completion dates that lined up with Gilead’s repeatedly confirmed plans to post the initial results in Q1 and Q2. But the January and March completion dates were radically adjusted, just days ago, to November, 2022 and February, 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
